Scarica l'app Stockscreener
5.60
1.27%
0.07
Pre-mercato:
5.74
0.14
+2.50%
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit - The Manila Times
Glioblastoma biomarkers, imaging and trials: Candel to outline data in Boston - Stock Titan
Candel Therapeutics to highlight glioblastoma immunotherapy data at Boston summit - Proactive financial news
Is Candel Therapeutics Inc. stock a safe haven assetQuarterly Risk Review & Verified High Yield Trade Plans - mfd.ru
Precision Trading with Candel Therapeutics Inc. (CADL) Risk Zones - Stock Traders Daily
Ideas Watch: Will Candel Therapeutics Inc face regulatory challengesQuarterly Portfolio Report & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update - TipRanks
Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Malaysian Reserve
Candel Therapeutics announces inducement grants under Nasdaq listing rule - marketscreener.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - TradingView
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is Candel Therapeutics Inc. on track to beat earningsJuly 2025 Highlights & Verified Swing Trading Watchlist - mfd.ru
Candel Therapeutics, Inc. (CADL) Stock Analysis: Exploring a Potential 224% Upside in Biotech Innovation - DirectorsTalk Interviews
Technical Reactions to CADL Trends in Macro Strategies - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is the earnings history of Candel Therapeutics Inc.Insider Selling & Precise Trade Entry Recommendations - mfd.ru
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Candel Therapeutics, Inc. (CADL) Stock Analysis: A Biotech With 195.63% Potential Upside - DirectorsTalk Interviews
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research - MarketBeat
New Strong Sell Stocks for January 20th - sharewise.com
Is Candel Therapeutics Inc. stock affected by interest rate hikesQuarterly Growth Report & Growth Focused Investment Plans - bollywoodhelpline.com
Trading the Move, Not the Narrative: (CADL) Edition - Stock Traders Daily
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st
Aug Highlights: Will Xometry Inc stock recover after earningsPortfolio Risk Report & Pattern Based Trade Signal System - baoquankhu1.vn
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Sectors Review: Will Candel Therapeutics Inc stock maintain momentum in 2025Earnings Trend Report & Consistent Profit Alerts - Bộ Nội Vụ
Valuation Update: Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Can Candel Therapeutics Inc. stock attract ESG capital inflows2025 Momentum Check & Consistent Return Strategy Ideas - Улправда
Aug Volume: Will Candel Therapeutics Inc. stock outperform tech sector in 20252025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - Улправда
Can Candel Therapeutics Inc. stock sustain free cash flow growth2025 Valuation Update & Trade Opportunity Analysis - Улправда
Will Candel Therapeutics Inc. stock outperform tech sector in 2025IPO Watch & Consistent Profit Trade Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS) - The Globe and Mail
(CADL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Understanding the Setup: (CADL) and Scalable Risk - Stock Traders Daily
Candel Therapeutics, Inc.(NasdaqGM: CADL) added to NASDAQ Biotechnology Index - marketscreener.com
Can Candel Therapeutics Inc. stock surprise with earnings upside2025 Momentum Check & Risk Adjusted Buy/Sell Alerts - Улправда
Candel Therapeutics Earnings Notes - Trefis
Why Candel Therapeutics Inc. stock is rated strong buyOil Prices & Stepwise Swing Trade Plans - Улправда
Will Candel Therapeutics Inc. stock outperform Dow Jones index2025 AllTime Highs & Long-Term Capital Growth Ideas - DonanımHaber
Will Candel Therapeutics Inc. stock maintain growth storyStop Loss & AI Powered Buy and Sell Recommendations - Улправда
Bear Alert: Why Candel Therapeutics Inc. stock is rated strong buyWeekly Gains Summary & Weekly Breakout Watchlists - Улправда
How (CADL) Movements Inform Risk Allocation Models - Stock Traders Daily
B of A Securities Downgrades Candel Therapeutics (CADL) - MSN
Candel Therapeutics, Inc. $CADL is Acorn Capital Advisors LLC's 5th Largest Position - MarketBeat
Is Candel Therapeutics On The Move With Pipeline Progress And Market Momentum? - RTTNews
Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On Thursday - Benzinga
Brookline Capital Management Weighs in on CADL Q4 Earnings - MarketBeat
Citi Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Candel Therapeutics (NASDAQ:CADL) Shares Little Changed on Clinical-Stage Progress - Kalkine Media
Stephens Reaffirms Overweight Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Candel Therapeutics (CADL) Maintains "Overweight" Rating by Step - GuruFocus
CADL: CAN-2409's phase 3 success and strong market outlook drive launch readiness and pipeline expansion - TradingView
CADL: CAN-2409's phase III success and strong market readiness position it for rapid adoption and growth - TradingView — Track All Markets
CADL: Late-stage immunotherapy programs advance toward commercialization and regulatory milestones - TradingView — Track All Markets
Candel Therapeutics, Inc. Hosts R&D Day Highlighting Viral Immunotherapy Advances - TradingView — Track All Markets
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 271% Potential Upside in Biotech - DirectorsTalk Interviews
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):